Align Technology (ALGN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Apr, 2026Executive summary
Achieved record FY 2025 revenues of $4.0 billion, with $3.2 billion from clear aligners and $789.6 million from systems and services.
Operating margin reached 13.5% GAAP and 21.8% non-GAAP; diluted net income per share was $5.65 GAAP, $10.51 non-GAAP.
Repurchased $466 million in common stock and ended the year with over $1 billion in cash and no debt.
International growth was strong, especially in EMEA, Latin America, and APAC; North America stabilized.
Continued investment in AI-driven diagnostics, digital platforms, and sustainability initiatives.
Voting matters and shareholder proposals
Proposal 1: Election of ten directors, all currently serving, with 90% independence.
Proposal 2: Advisory vote to approve executive compensation, emphasizing pay-for-performance.
Proposal 3: Ratification of PricewaterhouseCoopers LLP as independent auditor.
Proposal 4: Ratification of bylaw provision allowing shareholders with 25% ownership for one year to call special meetings.
Board of directors and corporate governance
Board consists of ten directors post-meeting, with a majority independent and diverse backgrounds.
Four standing committees: Audit, Compensation and Human Capital, Nominating and Governance, and Technology.
Annual board and committee evaluations, robust stockholder engagement, and succession planning.
Recent governance enhancements include proxy access, elimination of supermajority voting, and expanded special meeting rights.
Latest events from Align Technology
- Voting standard for Proposal 4 clarified; majority approval of shares present or represented required.ALGN
Proxy filing17 Apr 2026 - Record Q4 and FY2025 revenues, strong Clear Aligner and DSO growth, and positive 2026 outlook.ALGN
Q4 202517 Apr 2026 - Virtual Annual Meeting to address director elections, compensation, auditor, and bylaw proposals.ALGN
Proxy filing7 Apr 2026 - Record revenues, robust governance, and enhanced shareholder rights highlight this year's proxy.ALGN
Proxy filing27 Mar 2026 - Broad-based growth, strong DSO performance, and stable outlook drive confidence for 2026.ALGN
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Strong growth in Europe and APAC, with product innovation and efficiency boosting margins.ALGN
Leerink Global Healthcare Conference 202610 Mar 2026 - Digital dentistry expansion, AI-driven innovation, and global growth drive strong financial outlook.ALGN
Investor Day 20253 Feb 2026 - Q2 2024 revenue up 2.6% to $1.03B; margin pressured by FX, mix, and legal settlement.ALGN
Q2 20243 Feb 2026 - Q1 2024 growth fueled by AI, 3D printing, and new digital orthodontic products.ALGN
The 44th Annual William Blair Growth Stock Conference31 Jan 2026